Apple Must Face Apple Watch Patent Claims, Fed Circ. Affirms – Blake Brittain posted an article on Reuters.com about how Apple “lost its bid to escape patent infringement claims over its Apple Watch technology . . . at the U.S. Court of Appeals for the Federal Circuit.”
Teva’s Generic Label Not Skinny Enough to Protect from $234M Damages to GSK – In an article written by Khadijah M. Silver on MedCityNews.com, Silver reports that the Federal Circuit issued a “controversial” decision about Teva’s “skinny label.”
Apple Must Face Apple Watch Patent Claims, Fed Circ. Affirms
Reported by Blake Brittain on Reuters.com
An article written by Blake Brittain for Reuters reports on the Federal Circuit’s decision in Omni MedSci Inc. v. Apple Inc., where “Apple Inc lost its bid to escape patent infringement claims over its Apple Watch technology brought by a University of Michigan professor’s biomedical laser company.” Brittain notes the dissent by Circuit Judge Pauline Newman “arguing the majority ‘overturns decades of unchallenged understanding and implementation of the University’s employment agreement and policy documents.'”
Teva’s Generic Label Not Skinny Enough to Protect from $234M Damages to GSK
Reported by Khadijan M. Silver on MedCityNews.com
On MedCityNews.com, Khadijah M. Silver reports on the Federal Circuit’s 2-1 decision finding “that Teva swayed doctors away from using GlaxoSmithKline’s drug Coreg (carvedilol) for a use of its drug that was still protected under patent law.” Silver explains that the court found it was reasonable that a jury decided Teva was an infringer and “[hit] Teva with $234 million in damages for GSK’s lost sales and another $1.5 million in royalties.” Silver notes that the court showed “how each of the possible grounds the jury had considered for inducement of infringement could have been found compelling by the jury, and how the finding that Teva induced [infringement] was supported by the evidence as a whole.”